Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S

SARS-CoV-2 vaccines BNT162b2, mRNA-1273, and Ad26.COV2.S received emergency use authorization by the U.S. Food and Drug Administration in 2020/2021. Individuals being vaccinated were invited to participate in a prospective longitudinal comparative study of immune responses elicited by the three vacc...

Descripción completa

Detalles Bibliográficos
Autores principales: Barbeau, Dominique J., Martin, Judith M., Carney, Emily, Dougherty, Emily, Doyle, Joshua D., Dermody, Terence S., Hoberman, Alejandro, Williams, John V., Michaels, Marian G., Alcorn, John F., Paul Duprex, W., McElroy, Anita K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258461/
https://www.ncbi.nlm.nih.gov/pubmed/35794181
http://dx.doi.org/10.1038/s41541-022-00504-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258461/
https://www.ncbi.nlm.nih.gov/pubmed/35794181
http://dx.doi.org/10.1038/s41541-022-00504-x

Ejemplares similares